1,720,971 research outputs found
Epirubicin and its metabolites levels in experimental liver metastases after different administration routes
No full textEpiadryamicin concentration in experimental hepatic metastases after bolus or continuous infusion through systemic or locoregional routes
No full textEpyadriamicin concentration in experimental hepatic metastases after bolus or continuous infusion through systemic or locoregional routes
No full textNatural history of the neoplastic locoregional disease:clinical and pathological patterns
No full textEmbolisation of arteriovenous intrahepatic fistulas associated with diffuse haemangiomatosis of the liver. Report of a case in an adult and review of the literature
No full textDiffuse hepatic haemangiomatosis is rare in adults. Association with high output intrahepatic arteriovenous fistulas has been described. To avoid heart failure complications, treatment is essential. The second case in the literature, treated with repeated transcatheter arterial embolizations (TAE) but complicated by infection of multiple haemangiomas and by Kasabach-Merritt syndrome, is presented. Complications were due to the persistent presence of haemangiomas within the liver, where an impressive collection of platelets and a superinfection were observed. Therefore, to treat arteriovenous fistula-related problems and to prevent possible complications due to persistence of the haemangiomas, surgical removal should be preferred over embolisation
Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout.
No full text
Temporary occlusion of the hepatic artery plus infusion and systemic chemotherapy for inoperable cancer of the liver.
No full textI.F. 0.169
Abstract: Fourteen patients with diffuse tumors of the liver were treated with temporary occlusion of the hepatic artery (HA) by an external tourniquet followed by infusion and systemic chemotherapy. Three patients had primary neoplasms (one hepatocarcinoma and two cholangiocarcinomas) and eleven had metastatic disease (nine from carcinoma of the colon and rectum, one from retroperitoneal liposarcoma, and one from pulmonary small cell cancer). Infusion chemotherapy in all patients was based on 5-FU, Mitomycin and Vincristine. Systemic chemotherapy was FIVB in metastatic carcinoma and Adriamycin in primary liver tumors. All patients showed improvement of the performance status according to the Karnofsky Index. Objective response (OR) was present in 54% of cases. At present, median survival time in 12.5 months. Aggressive treatment combining hepatic ischemia with infusion and systemic polychemotherapy seems to provide an effective method of palliation in diffuse tumors of the liver. Delayed occlusion by an external tourniquet appears safer than intraoperative ligation of the HA
- …
